Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotine + silver salt is a hypothetical or experimental combination drug composed of **nicotine** (typically used in nicotine replacement therapy for smoking cessation) and a **silver salt** (such as silver acetate). Nicotine acts as a nicotinic acetylcholine receptor agonist, reducing withdrawal symptoms and cravings in individuals attempting to quit smoking. Silver salts, particularly silver acetate, have historically been used as aversive agents in smoking cessation by producing an unpleasant metallic taste when combined with cigarette smoke. The rationale is to combine the aversive conditioning effect of the silver salt with the withdrawal-mitigating effect of nicotine, potentially supporting smoking cessation by two complementary mechanisms. However, there is no evidence of a marketed or commonly used product specifically containing this exact combination, and there is little evidence for the efficacy of silver salts in this context relative to standard nicotine replacement therapy[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotine + silver salt.